How Does Mounjaro Work for Weight Loss?

How Does Mounjaro Work for Weight Loss?#

Mounjaro works by mimicking two natural hormones in your gut - GLP-1 and GIP - that control appetite and blood sugar. When you inject tirzepatide (the active ingredient), it triggers the same signals these hormones would, making you feel full, reducing cravings, and slowing food movement through your stomach.

This dual-hormone approach is why Mounjaro often outperforms single-hormone treatments like Wegovy. Clinical trials show people can lose 20-22% of their body weight over 72 weeks - results comparable to bariatric surgery but without the invasive procedure.

What Is Mounjaro?#

Mounjaro is a once-weekly injection containing tirzepatide, originally developed for type 2 diabetes. The MHRA approved it for weight management in November 2023 after impressive clinical trial results.

You're eligible for Mounjaro if you have a BMI of 30 or above, or BMI 27-29.9 with a weight-related health condition like high blood pressure or sleep apnoea. It's not suitable if you're pregnant, breastfeeding, under 18, or have certain pancreas or thyroid conditions.

The medication comes as a pre-filled pen (KwikPen) that you inject into your thigh, stomach, or upper arm once weekly. Most people start on 2.5mg and gradually increase to 5mg, 10mg, or 15mg depending on how well they tolerate it.

The Science: Two Hormones Are Better Than One#

When you eat, your intestines release two key hormones: GLP-1 and GIP (glucose-dependent insulinotropic polypeptide). These "incretin" hormones work together to:

• Signal fullness to your brain
• Stimulate insulin release to control blood sugar
• Slow gastric emptying (how quickly food leaves your stomach)
• Reduce glucagon production (a hormone that raises blood sugar)

Tirzepatide acts as a "dual agonist" - it binds to both GLP-1 and GIP receptors, essentially fooling your body into thinking you've just eaten and should feel satisfied.

Why Target Both Hormones?#

For years, scientists focused solely on GLP-1 - that's how Wegovy and Saxenda work. But research showed that adding GIP activation significantly improves results. In head-to-head trials, tirzepatide consistently produces greater weight loss than semaglutide (Wegovy's active ingredient).

GIP receptors are found throughout the brain, including areas that control food reward and pleasure. This may explain why people on Mounjaro report less "food noise" - that constant mental chatter about what to eat next.

How Mounjaro Changes Your Body#

Appetite Suppression#

The most noticeable effect is reduced hunger. Tirzepatide activates GLP-1 receptors in your hypothalamus (the brain's appetite control centre), sending strong "I'm full" signals even when you haven't eaten much.

It also suppresses ghrelin, often called the "hunger hormone." Lower ghrelin means fewer hunger pangs between meals and less likelihood of late-night snacking.

Slower Gastric Emptying#

Mounjaro slows how quickly food moves from your stomach to your small intestine. This keeps you feeling full longer and prevents blood sugar spikes that can trigger more hunger.

Many people find they're satisfied with smaller portions and don't experience the energy crashes that often lead to cravings.

Improved Insulin Sensitivity#

Even if you don't have diabetes, better insulin sensitivity helps with weight management. When your cells respond properly to insulin, your body is less likely to store excess calories as fat.

This is particularly important because insulin resistance affects up to 40% of young adults in developed countries, often without them knowing it.

Reduced Food Cravings#

Brain imaging studies show fascinating changes in people taking tirzepatide. When shown pictures of high-calorie foods, their brains show less activation in reward centres compared to people taking placebo.

This translates to real-world changes: less thinking about food, fewer impulsive food choices, and reduced emotional eating.

Timeline: What to Expect#

You might notice appetite changes within hours of your first injection, but meaningful weight loss takes time:

Week 1-4: Appetite reduction, possible mild nausea as your body adjusts Month 1-2: First noticeable weight loss (typically 3-4% of starting weight) Month 6: Average weight loss of 10-15% with the 10-15mg doses Month 12-18: Peak results - 20-22% weight loss in clinical trials

Results vary significantly between individuals. Factors affecting your response include:

• Starting weight and BMI
• Diet and exercise habits
• Genetic factors
• Other medications
• Adherence to treatment

If you're not seeing results after 3-4 months, speak to your prescriber about adjusting your dose or exploring alternatives.

Side Effects and Management#

Most side effects are gastrointestinal and tend to improve as your body adjusts:

Common (affecting more than 10% of people):

• Nausea
• Vomiting
• Diarrhoea
• Constipation
• Reduced appetite
• Abdominal pain

Less common but important:

• Gallbladder problems
• Pancreatitis (rare but serious)
• Kidney problems if you become severely dehydrated
• Diabetic retinopathy (in people with diabetes)

The key to minimising side effects is slow dose escalation and dietary adjustments. Eating smaller, lower-fat meals and staying well-hydrated helps significantly.

NHS Availability and Private Options#

Currently, NHS access to Mounjaro is extremely limited. It's only available through specialist weight management services for people with BMI ≥40 plus at least four weight-related health conditions.

For most people, private treatment is the only option. This typically costs £150-300 monthly, depending on your dose and provider.

If you're considering Mounjaro, Totiva's weight loss service offers comprehensive consultations with UK pharmacists who can assess your suitability and provide ongoing support throughout your treatment journey.

Maximising Your Results#

Mounjaro isn't a magic bullet - it works best alongside lifestyle changes:

Dietary recommendations:

• Focus on protein-rich foods (aim for 1.2-1.6g per kg body weight daily)
• Eat plenty of vegetables and fibre
• Reduce ultra-processed foods and added sugars
• Stay hydrated (many side effects worsen with dehydration)

Exercise guidelines:

• Maintain muscle mass with resistance training 2-3 times weekly
• Include regular cardiovascular exercise
• Start gradually if you're new to exercise

Monitoring:

• Regular check-ins with your prescriber
• Blood tests to monitor kidney function and blood sugar
• Track weight loss progress and side effects

Alternatives to Consider#

If Mounjaro isn't suitable or available, other options include:

Other GLP-1 medications:

• Wegovy (semaglutide) - weekly injection
• Saxenda (liraglutide) - daily injection
• Orlistat - oral tablet that blocks fat absorption

Future treatments:

• Retatrutide (triple-hormone agonist) showing even greater weight loss in trials
• Oral GLP-1 medications in development

Non-medication approaches:

• NHS Tier 3 weight management programmes
• Private dietitian support
• Cognitive behavioural therapy for eating behaviours
• Bariatric surgery for severe obesity

Is Mounjaro Right for You?#

Mounjaro represents a genuine breakthrough in weight management, offering results that were previously only achievable through surgery. However, it's not suitable for everyone and requires long-term commitment.

Consider Mounjaro if you:

• Have struggled with traditional diet and exercise approaches
• Meet the BMI criteria
• Are prepared for potential side effects
• Can commit to long-term lifestyle changes
• Understand this is likely a long-term treatment

The medication works by fundamentally changing how your body responds to food, but maintaining weight loss typically requires continuing treatment. Most people regain weight if they stop, though the lifestyle habits learned during treatment can help maintain some benefits.

If you'd like to explore whether Mounjaro might be suitable for your situation, Totiva's pharmacist-led consultations can provide personalised advice and ongoing support to help you achieve sustainable weight management results.